Silverback Therapeutics (NASDAQ:SBTX) Sets New 12-Month High – Time to Buy?
by Doug Wharley · The Cerbat GemSilverback Therapeutics, Inc. (NASDAQ:SBTX – Get Free Report) hit a new 52-week high during trading on Tuesday . The stock traded as high as $14.04 and last traded at $13.88, with a volume of 654897 shares. The stock had previously closed at $13.66.
Silverback Therapeutics Trading Down 1.2 %
The firm has a market cap of $494.36 million, a P/E ratio of -5.67 and a beta of 0.60. The business’s fifty day simple moving average is $12.66 and its 200-day simple moving average is $10.47.
About Silverback Therapeutics
Silverback Therapeutics, Inc, a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver.
Featured Articles
- Five stocks we like better than Silverback Therapeutics
- How to Invest in Small Cap Stocks
- MercadoLibre Targets Double-Digit Upside with Argentina Boom
- Retail Stocks Investing, Explained
- Domino’s Pizza Stock Delivers: A Hot Buy for Growth Investors
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- 3 Small-Cap Stocks Ready to Deliver Significant Growth